SPYRE THERAPEUTICS INC (SYRE) — insider trading
Health Care · NASDAQ
SPYRE THERAPEUTICS INC (SYRE) has 125 reported SEC Form 4 insider transactions in our data, including 66 open-market sales among the most recent 100 (latest 2026-10-01).
Recent Form 4 transactions
Showing the 100 most recent of 125 recorded transactions. See all on SEC EDGAR →
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Turtle Cameron | Director, Officer (Chief Executive Officer) | Open-market sale | 100 | $93.91 | $9.4K | Form 4 |
| 2026-10-01 | Turtle Cameron | Director, Officer (Chief Executive Officer) | Open-market sale | 4,990 | $93.37 | $465.9K | Form 4 |
| 2026-10-01 | Turtle Cameron | Director, Officer (Chief Executive Officer) | Open-market sale | 3,989 | $92.31 | $368.2K | Form 4 |
| 2026-10-01 | Turtle Cameron | Director, Officer (Chief Executive Officer) | Open-market sale | 2,638 | $91.49 | $241.4K | Form 4 |
| 2026-10-01 | Turtle Cameron | Director, Officer (Chief Executive Officer) | Open-market sale | 2,683 | $90.10 | $241.7K | Form 4 |
| 2026-10-01 | Turtle Cameron | Director, Officer (Chief Executive Officer) | Open-market sale | 600 | $89.14 | $53.5K | Form 4 |
| 2026-10-01 | King-Jones Heidy | Officer (See Remarks) | Option exercise / conversion (derivative) | 28,933 | — | $0 | Form 4 |
| 2026-10-01 | King-Jones Heidy | Officer (See Remarks) | Open-market sale | 2,600 | $93.46 | $243.0K | Form 4 |
| 2026-10-01 | King-Jones Heidy | Officer (See Remarks) | Open-market sale | 2,100 | $92.70 | $194.7K | Form 4 |
| 2026-10-01 | King-Jones Heidy | Officer (See Remarks) | Open-market sale | 7,228 | $91.35 | $660.3K | Form 4 |
| 2026-10-01 | King-Jones Heidy | Officer (See Remarks) | Open-market sale | 16,605 | $90.35 | $1.50M | Form 4 |
| 2026-10-01 | King-Jones Heidy | Officer (See Remarks) | Open-market sale | 400 | $89.24 | $35.7K | Form 4 |
| 2026-10-01 | King-Jones Heidy | Officer (See Remarks) | Option exercise / conversion | 28,933 | $14.50 | $419.5K | Form 4 |
| 2026-10-01 | Burrows Scott L | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 7,500 | — | $0 | Form 4 |
| 2026-10-01 | Burrows Scott L | Officer (Chief Financial Officer) | Open-market sale | 229 | $93.57 | $21.4K | Form 4 |
| 2026-10-01 | Burrows Scott L | Officer (Chief Financial Officer) | Open-market sale | 3,071 | $92.95 | $285.4K | Form 4 |
| 2026-10-01 | Burrows Scott L | Officer (Chief Financial Officer) | Open-market sale | 2,100 | $91.92 | $193.0K | Form 4 |
| 2026-10-01 | Burrows Scott L | Officer (Chief Financial Officer) | Open-market sale | 1,500 | $90.27 | $135.4K | Form 4 |
| 2026-10-01 | Burrows Scott L | Officer (Chief Financial Officer) | Open-market sale | 600 | $89.07 | $53.4K | Form 4 |
| 2026-10-01 | Burrows Scott L | Officer (Chief Financial Officer) | Option exercise / conversion | 7,500 | $14.50 | $108.8K | Form 4 |
| 2026-09-30 | Burrows Scott L | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 17,500 | — | $0 | Form 4 |
| 2026-09-30 | Burrows Scott L | Officer (Chief Financial Officer) | Open-market sale | 17,500 | $89.89 | $1.57M | Form 4 |
| 2026-09-30 | Burrows Scott L | Officer (Chief Financial Officer) | Option exercise / conversion | 17,500 | $14.50 | $253.8K | Form 4 |
| 2026-09-02 | King-Jones Heidy | Officer (See Remarks) | Option exercise / conversion (derivative) | 400 | — | $0 | Form 4 |
| 2026-09-02 | King-Jones Heidy | Officer (See Remarks) | Open-market sale | 400 | $90.00 | $36.0K | Form 4 |
| 2026-09-02 | King-Jones Heidy | Officer (See Remarks) | Option exercise / conversion | 400 | $14.50 | $5.8K | Form 4 |
| 2026-09-02 | Burrows Scott L | Officer (Chief Financial Officer) | Open-market sale | 18,232 | $89.35 | $1.63M | Form 4 |
| 2026-09-01 | Turtle Cameron | Director, Officer (Chief Executive Officer) | Open-market sale | 400 | $89.07 | $35.6K | Form 4 |
| 2026-09-01 | Turtle Cameron | Director, Officer (Chief Executive Officer) | Open-market sale | 3,700 | $88.06 | $325.8K | Form 4 |
| 2026-09-01 | Turtle Cameron | Director, Officer (Chief Executive Officer) | Open-market sale | 8,400 | $87.15 | $732.1K | Form 4 |
| 2026-09-01 | Turtle Cameron | Director, Officer (Chief Executive Officer) | Open-market sale | 2,500 | $86.36 | $215.9K | Form 4 |
| 2026-09-01 | King-Jones Heidy | Officer (See Remarks) | Option exercise / conversion (derivative) | 27,999 | — | $0 | Form 4 |
| 2026-09-01 | King-Jones Heidy | Officer (See Remarks) | Open-market sale | 400 | $89.38 | $35.8K | Form 4 |
| 2026-09-01 | King-Jones Heidy | Officer (See Remarks) | Open-market sale | 6,206 | $88.17 | $547.2K | Form 4 |
| 2026-09-01 | King-Jones Heidy | Officer (See Remarks) | Open-market sale | 16,548 | $87.20 | $1.44M | Form 4 |
| 2026-09-01 | King-Jones Heidy | Officer (See Remarks) | Open-market sale | 4,845 | $86.40 | $418.6K | Form 4 |
| 2026-09-01 | King-Jones Heidy | Officer (See Remarks) | Option exercise / conversion | 27,999 | $14.50 | $406.0K | Form 4 |
| 2026-09-01 | Burrows Scott L | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 7,500 | — | $0 | Form 4 |
| 2026-09-01 | Burrows Scott L | Officer (Chief Financial Officer) | Open-market sale | 200 | $89.04 | $17.8K | Form 4 |
| 2026-09-01 | Burrows Scott L | Officer (Chief Financial Officer) | Open-market sale | 2,016 | $88.03 | $177.5K | Form 4 |
| 2026-09-01 | Burrows Scott L | Officer (Chief Financial Officer) | Open-market sale | 4,384 | $87.11 | $381.9K | Form 4 |
| 2026-09-01 | Burrows Scott L | Officer (Chief Financial Officer) | Open-market sale | 900 | $86.25 | $77.6K | Form 4 |
| 2026-09-01 | Burrows Scott L | Officer (Chief Financial Officer) | Option exercise / conversion | 7,500 | $14.50 | $108.8K | Form 4 |
| 2026-08-07 | Albers Jeffrey W. | Director | Option exercise / conversion (derivative) | 5,000 | — | $0 | Form 4 |
| 2026-08-07 | Albers Jeffrey W. | Director | Open-market sale | 10,000 | $104.68 | $1.05M | Form 4 |
| 2026-08-07 | Albers Jeffrey W. | Director | Open-market sale | 8,000 | $104.38 | $835.0K | Form 4 |
| 2026-08-07 | Albers Jeffrey W. | Director | Open-market sale | 5,000 | $104.47 | $522.4K | Form 4 |
| 2026-08-07 | Albers Jeffrey W. | Director | Option exercise / conversion | 5,000 | $10.39 | $52.0K | Form 4 |
| 2026-08-03 | Turtle Cameron | Director, Officer (Chief Executive Officer) | Open-market sale | 16 | $97.46 | $1.6K | Form 4 |
| 2026-08-03 | Turtle Cameron | Director, Officer (Chief Executive Officer) | Open-market sale | 1,392 | $96.82 | $134.8K | Form 4 |
| 2026-08-03 | Turtle Cameron | Director, Officer (Chief Executive Officer) | Open-market sale | 5,635 | $95.93 | $540.6K | Form 4 |
| 2026-08-03 | Turtle Cameron | Director, Officer (Chief Executive Officer) | Open-market sale | 7,157 | $95.10 | $680.6K | Form 4 |
| 2026-08-03 | Turtle Cameron | Director, Officer (Chief Executive Officer) | Open-market sale | 800 | $93.97 | $75.2K | Form 4 |
| 2026-08-03 | Burrows Scott L | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 7,500 | — | $0 | Form 4 |
| 2026-08-03 | Burrows Scott L | Officer (Chief Financial Officer) | Open-market sale | 100 | $97.10 | $9.7K | Form 4 |
| 2026-08-03 | Burrows Scott L | Officer (Chief Financial Officer) | Open-market sale | 2,300 | $96.30 | $221.5K | Form 4 |
| 2026-08-03 | Burrows Scott L | Officer (Chief Financial Officer) | Open-market sale | 5,100 | $95.21 | $485.6K | Form 4 |
| 2026-08-03 | Burrows Scott L | Officer (Chief Financial Officer) | Option exercise / conversion | 7,500 | $14.50 | $108.8K | Form 4 |
| 2026-07-01 | Turtle Cameron | Director, Officer (Chief Executive Officer) | Open-market sale | 590 | $88.91 | $52.5K | Form 4 |
| 2026-07-01 | Turtle Cameron | Director, Officer (Chief Executive Officer) | Open-market sale | 4,234 | $88.12 | $373.1K | Form 4 |
| 2026-07-01 | Turtle Cameron | Director, Officer (Chief Executive Officer) | Open-market sale | 10,176 | $87.44 | $889.8K | Form 4 |
| 2026-07-01 | Sloan Sheldon | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 8,334 | — | $0 | Form 4 |
| 2026-07-01 | Sloan Sheldon | Officer (Chief Medical Officer) | Open-market sale | 1,834 | $88.34 | $162.0K | Form 4 |
| 2026-07-01 | Sloan Sheldon | Officer (Chief Medical Officer) | Open-market sale | 6,500 | $87.52 | $568.9K | Form 4 |
| 2026-07-01 | Sloan Sheldon | Officer (Chief Medical Officer) | Option exercise / conversion | 8,334 | $27.46 | $228.9K | Form 4 |
| 2026-07-01 | Burrows Scott L | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 7,500 | — | $0 | Form 4 |
| 2026-07-01 | Burrows Scott L | Officer (Chief Financial Officer) | Open-market sale | 1,725 | $88.37 | $152.4K | Form 4 |
| 2026-07-01 | Burrows Scott L | Officer (Chief Financial Officer) | Open-market sale | 5,775 | $87.55 | $505.6K | Form 4 |
| 2026-07-01 | Burrows Scott L | Officer (Chief Financial Officer) | Option exercise / conversion | 7,500 | $14.50 | $108.8K | Form 4 |
| 2026-06-25 | Burrows Scott L | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 15,000 | — | $0 | Form 4 |
| 2026-06-25 | Burrows Scott L | Officer (Chief Financial Officer) | Open-market sale | 10,000 | $87.14 | $871.4K | Form 4 |
| 2026-06-25 | Burrows Scott L | Officer (Chief Financial Officer) | Open-market sale | 5,000 | $87.12 | $435.6K | Form 4 |
| 2026-06-25 | Burrows Scott L | Officer (Chief Financial Officer) | Option exercise / conversion | 15,000 | $14.50 | $217.5K | Form 4 |
| 2026-06-23 | Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Kiselak Tomas; Harwin Peter Evan | Director | Conversion of derivative (derivative) | 16,667 | — | $0 | Form 4 |
| 2026-06-23 | Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Kiselak Tomas; Harwin Peter Evan | Director | Open-market sale | 4,684,781 | $85.31 | $399.66M | Form 4 |
| 2026-06-23 | Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Kiselak Tomas; Harwin Peter Evan | Director | Conversion of derivative | 666,680 | — | — | Form 4 |
| 2026-06-22 | HENDERSON MICHAEL THOMAS | Director | Open-market sale | 20,000 | $100.00 | $2.00M | Form 4 |
| 2026-06-03 | Sloan Sheldon | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 8,333 | — | $0 | Form 4 |
| 2026-06-03 | Sloan Sheldon | Officer (Chief Medical Officer) | Open-market sale | 8,333 | $75.00 | $625.0K | Form 4 |
| 2026-06-03 | Sloan Sheldon | Officer (Chief Medical Officer) | Option exercise / conversion | 8,333 | $27.46 | $228.8K | Form 4 |
| 2026-06-01 | Burrows Scott L | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 7,500 | — | $0 | Form 4 |
| 2026-06-01 | Burrows Scott L | Officer (Chief Financial Officer) | Open-market sale | 3,100 | $72.06 | $223.4K | Form 4 |
| 2026-06-01 | Burrows Scott L | Officer (Chief Financial Officer) | Open-market sale | 2,599 | $70.77 | $183.9K | Form 4 |
| 2026-06-01 | Burrows Scott L | Officer (Chief Financial Officer) | Open-market sale | 1,801 | $69.75 | $125.6K | Form 4 |
| 2026-06-01 | Burrows Scott L | Officer (Chief Financial Officer) | Option exercise / conversion | 7,500 | $14.50 | $108.8K | Form 4 |
| 2026-06-01 | Turtle Cameron | Director, Officer (Chief Executive Officer) | Open-market sale | 3,294 | $71.38 | $235.1K | Form 4 |
| 2026-06-01 | Turtle Cameron | Director, Officer (Chief Executive Officer) | Open-market sale | 8,149 | $70.50 | $574.5K | Form 4 |
| 2026-06-01 | Turtle Cameron | Director, Officer (Chief Executive Officer) | Open-market sale | 3,557 | $69.40 | $246.9K | Form 4 |
| 2026-05-27 | Milligan Sandra | Director | Grant / award / vesting (derivative) | 8,026 | — | $0 | Form 4 |
| 2026-05-27 | McKenna Mark C. | Director | Grant / award / vesting (derivative) | 8,026 | — | $0 | Form 4 |
| 2026-05-27 | Stelzer Laurie | Director | Grant / award / vesting (derivative) | 8,026 | — | $0 | Form 4 |
| 2026-05-27 | HENDERSON MICHAEL THOMAS | Director | Grant / award / vesting (derivative) | 8,026 | — | $0 | Form 4 |
| 2026-05-27 | Albers Jeffrey W. | Director | Grant / award / vesting (derivative) | 8,026 | — | $0 | Form 4 |
| 2026-05-27 | Fairmount Funds Management LLC; Kiselak Tomas; Fairmount Healthcare Fund II L.P. | Director | Grant / award / vesting (derivative) | 8,026 | — | $0 | Form 4 |
| 2026-05-08 | HENDERSON MICHAEL THOMAS | Director | Open-market sale | 19,269 | $75.35 | $1.45M | Form 4 |
| 2026-05-08 | HENDERSON MICHAEL THOMAS | Director | Open-market sale | 24,814 | $74.76 | $1.86M | Form 4 |
| 2026-05-08 | HENDERSON MICHAEL THOMAS | Director | Open-market sale | 33,513 | $73.72 | $2.47M | Form 4 |
| 2026-05-08 | HENDERSON MICHAEL THOMAS | Director | Open-market sale | 2,404 | $72.57 | $174.5K | Form 4 |
| 2026-05-01 | Turtle Cameron | Director, Officer (Chief Executive Officer) | Open-market sale | 300 | $74.96 | $22.5K | Form 4 |
| 2026-05-01 | Turtle Cameron | Director, Officer (Chief Executive Officer) | Open-market sale | 1,700 | $74.23 | $126.2K | Form 4 |
Ask the chat about SYRE's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: SPYRE THERAPEUTICS INC (SYRE).
Last updated 2026-10-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.